Baxter International 146 million dollars to expand China market

Nyse:bax, the US medical products and equipment maker, announced 15th that its board has approved a 146 million dollar investment plan to update and expand its current production lines in Guangzhou, Suzhou, Tianjin and Shanghai. This investment will enable Baxter International to meet the growing demand for intravenous fluids and peritoneal dialysis fluids in China in the future.　　Over the past few years, Baxter International has invested more than 250 million dollars in China, setting up five factories and a research and development center.　　Baxter International China said that at present, the company has covered more than 200 cities in China, with the start of the new health reform, the company's products will gradually expand to the community and rural markets. Data show that Baxter was founded in 1931, mainly produces chronic diseases and critical diseases of the treatment products, including kidney treatment, drug infusion, biotechnology, anesthesia and clinical nutrition and other fields. 2008, the company's global sales amounted to 12.3 billion U.S. dollars, of which 60% from outside North America's Changbert Asia-Pacific region sales exceeded 1.44 billion U.S. dollars last year, sales in China about 200 million U.S. dollars.